) announced that its Cerilliant brand has launched four new
Certified Spiking Solutions of the corticosteroids pregnenolone,
17alpha-hydroxypregnenolone, cortisone, and
11-deoxycorticosterone at concentrations of 100 ug/mL in
methanol. The shares of Sigma-Aldrich rose as much as around 1.4%
during the trading hours following the news announcement.
The new solutions have all the requisites necessary for
applications ranging from diagnostic testing and clinical
chemistry to endocrinology and neonatal screening. The stable
quantitative solution format of Cerilliant's Spiking Solutions
provides the laboratory benefits such as increased efficiency of
labor and convenience of use.
The LC-MS/MS is well established for neonatal screening and
Pain management clinics are increasingly using LC-MS/MS methods
to quantify hormones such as pregnenolone,
17alpha-hydroxypregnenolone, and cortisone in patient serum.
These hormones serve as biomarkers of pain and indicators of
abnormal hormone production.
Cerilliant's catalog includes a wide range of analytical
standards for forensic, clinical, pharmaceutical, nutraceutical,
environmental testing and research with an emphasis on Certified
Solutions Standards and Certified Spiking Solutions. Cerilliant
provides solution-based reference standards for use in a wide
range of analytical applications ranging from clinical and
diagnostic testing, toxicology and therapeutic drug monitoring to
emerging applications in endocrinology, clinical chemistry and
Sigma-Aldrich , a life science and high technology company,
develops, manufactures, purchases, and distributes various
chemicals, biochemicals, and equipment worldwide.
Sigma-Aldrich carries a Zacks Rank #3 (Hold).
Other companies in the specialty chemicals space worth
Globe Specialty Metals, Inc.
International Flavors & Fragrances Inc.
Rockwood Holdings Inc.
), each carrying a Zacks Rank #2 (Buy).
GLOBE SPECIALTY (GSM): Free Stock Analysis
INTL F & F (IFF): Free Stock Analysis
ROCKWOOD HLDGS (ROC): Free Stock Analysis
SIGMA ALDRICH (SIAL): Free Stock Analysis
To read this article on Zacks.com click here.